PeopleBio, Inc. (KOSDAQ:304840)
South Korea · Delayed Price · Currency is KRW 777.00
+27.00 (3.60%)
At close: Apr 2, 2026
PeopleBio Revenue
PeopleBio had revenue of 1.18B KRW in the quarter ending September 30, 2025, with 23.20% growth. This brings the company's revenue in the last twelve months to 3.36B, down -23.26% year-over-year. In the year 2024, PeopleBio had annual revenue of 3.73B, down -16.20%.
Revenue (ttm)
3.36B
Revenue Growth
-23.26%
P/S Ratio
5.31
Revenue / Employee
72.94M
Employees
46
Market Cap
17.80B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 3.73B | -721.35M | -16.20% |
| Dec 31, 2023 | 4.45B | 8.02M | 0.18% |
| Dec 31, 2022 | 4.44B | 3.87B | 670.22% |
| Dec 31, 2021 | 577.08M | 69.23M | 13.63% |
| Dec 31, 2020 | 507.85M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Green Cross Medical Science | 108.41B |
| Seoulin Bioscience | 77.09B |
| Dx & Vx | 29.47B |
| Cytogen | 26.05B |
| Protia | 15.12B |
| HLB Panagene | 15.05B |
| 3billion | 11.71B |
| GENINUS | 10.48B |